News

BioGaia probiotic effectiveness confirmed

11 May 2016

BioGaia has announced that yet another meta-analysis confirms the effectiveness of its probiotic in infantile colic. In a newly presented systematic review, the proof of effect on infantile colic was further strengthened for L. reuteri Protectis.

BioGaia has announced that yet another meta-analysis confirms the effectiveness of its probiotic in infantile colic.

In a newly presented systematic review, the proof of effect on infantile colic was further strengthened for L. reuteri Protectis. The company notes that the review is the eighth meta-analysis evaluating L. reuteri Protectis’ effect on infantile colic.

Prior to the new review, BioGaia says that seven meta-analyses, evaluating different probiotics as well as non-probiotic treatments, have come to the same conclusion; that L. reuteri Protectis is effective in reducing crying time in colicky infants, especially in breastfed and mixed fed infants.

In the new, eighth review, with four studies on L. reuteri Protectis included, the proof was further strengthened, the company notes. It combined raw data from these trials (Individual Participant Data Meta-Analysis, IPDMA), a method that BioGaia says yields more reliable estimates of treatment effect compared to traditional meta-analyses based on published data only. The analysis was undertaken according to the methods recommended by Cochrane.

”A meta-analysis is considered the highest level of evidence of a health effect and now there are eight such meta-analyses with BioGaia ProTectis,” said Axel Sjöblad, Managing Director, BioGaia. “While this clearly confirms BioGaia ProTectis as the number one treatment for infants with colic, it also reassures health care professionals around the world that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients.”